送交者: whatsup 于 2006-4-27, 23:52:58:
Author Name task started on Fri Apr 28, 2006 at 12:39 AM
Explored by Author in CAPLUS and MEDLINE.
wei, yuquan
Selected 1 of 30 candidates
WEI YUQUAN (90 references)
Remove Duplicates
76 references were found (14 duplicates removed)
Refine by Language started
12 references were found when refined by Language "English"
Copyrights:
CAPLUS: Copyright © 2006 American Chemical Society. All Rights Reserved. (The UK patent material in this product/service is UK Crown copyright and is made available with permission. © Crown Copyright. The French (FR) patent material in this product/service is made available from Institut National de la Propriete Industrielle (INPI).)
MEDLINE: Produced by the U.S. National Library of Medicine
REGISTRY: Copyright © 2006 American Chemical Society. All Rights Reserved. (Some records contain information from GenBank(R). See also: Benson D.A., Karsch-Mizrachi I., Lipman D.J., Ostell J., Rapp B.A., Wheeler D.L. Genbank. Nucl. Acids Res. 28(1):15-18 (2000). Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.)
CASREACT: Copyright © 2006 American Chemical Society. All Rights Reserved. (In addition to reactions indexed by CAS, CASREACT contains reactions derived from the following sources: ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.)
CHEMLIST, CHEMCATS: Copyright © 2006 American Chemical Society. All Rights Reserved.
Bibliographic Information
Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain. Li, Zhengyu; Zhao, Xia; Yang, Jinliang; Wei, Yuquan. Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Peop. Rep. China. Science in China, Series C: Life Sciences (2005), 48(6), 648-657. Publisher: Science in China Press, CODEN: SCCLFO ISSN: 1006-9305. Journal written in English. AN 2006:166217 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
To compare the alterations in proteomes between cisplatin-treated and -untreated human ovarian cancer SKOV3 cells, and to explore the feasibility of proteomics in research about antitumor mechanisms of agents, SKOV3 cells were exposed to cisplatin (6 g/mL) for 6 h. Then, the cells were collected and solubilized and global proteins were extd. by lysis buffer; two-dimensional electrophoresis was conducted with the IPG readystrips as carriers; the gels were stained with Coomassie blue and alterations between gels were compared by PDQuest. Eventually, 11 spots with significant differences were selected and excised and the proteins were identified by PMF and MS/MS anal. The results revealed that exposure to cisplatin could notably increase expressions of some proteins, such as tropomyosin family, actin family, triosephosphate isomerase family, and HSP60, etc.; while expressions of some other proteins decreased, such as enolase family, etc. Those proteins were involved in cellular energy metab., transformation, apoptosis and morphol. maintenance, which suggested that alterations of those physiol. processes might be involved in anti-tumor mechanism of cisplatin.
Bibliographic Information
Serum proteomics study of the squamous cell carcinoma antigen 1 in tongue cancer. Huang, Xin; Wei, Yuquan; Li, Longjiang; Wen, Yuming; Yang, Jingliang; Liu, Bin; Song, Xin; Zhao, Jian. State Key Laboratory of Biotherapy, Sichuan University, Chendu City, Peop. Rep. China. Oral Oncology (2006), 42(1), 26-31. Publisher: Elsevier Ltd., CODEN: EJCCER ISSN: 1368-8375. Journal written in English. AN 2005:1348475 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
The identification of serum biomarkers as a means of the early diagnosis and finding possible therapeutic targets in cancers is of increasing interest. In the present study, cells of human tongue cancer cell line Tca8113 were s.c. inoculated into nude mice, while control nude mice were injected with phosphate-buffered saline. Two weeks after injection, serum from mice was collected for proteomic anal. using two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS). Comparing the serum 2-DE maps from the tumor-bearing mice with those produced from control mice, we found that squamous cell carcinoma antigen 1 was over-expressed only in tumor-bearing mice. Squamous cell carcinoma antigen 1 was also up-regulated in clin. tongue cancer patients by RT-PCR and Western-blotting. These results indicate that squamous cell carcinoma antigen 1 may be of great potential as the biomarker of tongue cancer and as the potential therapeutic target for gene therapy.
Bibliographic Information
Syntheses of carbamate derivatives of quercetin by reaction with amino acid ester isocyanates. Wu, Xianxue; Cheng, Li; Xiang, Dong; Wei, Yuquan. College of Chemistry, Sichuan University, Chengdu, Peop. Rep. China. Letters in Organic Chemistry (2005), 2(6), 535-538. Publisher: Bentham Science Publishers Ltd., CODEN: LOCEC7 ISSN: 1570-1786. Journal written in English. CAN 144:311813 AN 2005:943564 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
Synthesis of amino acid carbamate derivs. of quercetin, e.g. I, from partly protected quercetin and amino acid esters utilizing triphosgene as an auxiliary reagent was studied. A series of quercetin derivs. were obtained regioselectively by reaction with amino acid ester isocyanates under mild conditions and in high yields.
Bibliographic Information
Potential anticancer activity of tanshinone IIA against human breast cancer. Wang, Xiujie; Wei, Yuquan; Yuan, Shulan; Liu, Guanjian; Lu, Yanrong; Zhang, Jie; Wang, Wendong. Key Laboratory of Biotherapy of Human Diseases, West China Hospital, Ministry of Education, Sichuan University, Chengdu, Peop. Rep. China. International Journal of Cancer (2005), 116(5), 799-807. Publisher: Wiley-Liss, Inc., CODEN: IJCNAW ISSN: 0020-7136. Journal written in English. CAN 143:278640 AN 2005:842977 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
Tanshinone IIA is a deriv. of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. It has antioxidant properties and cytotoxic activity against multiple human cancer cell lines, inducing apoptosis and differentiation of some human cancer cell lines. Our purpose was to confirm its anticancer activity on human breast cancer in vitro and in vivo and to elucidate the mechanism of its activity. Human breast cancer cells were tested in vitro for cytotoxicity, colony formation inhibition, BrdU incorporation and gene expression profiling after treatment with tanshinone IIA. Seven nude mice bearing human breast infiltrating duct carcinoma orthotopically were tested for anticancer activity and expression of caspase-3 in vivo by s.c. injection of tanshinone IIA at a dose of 30 mg/kg 3 times/wk for 10 wk. Tanshinone IIA demonstrated a dose- and time-dependent inhibitory effect on cell growth (IC50 = 0.25 g/mL), and it significantly inhibited colony formation and BrdU incorporation of human breast cancer cells. Oligonucleotide microarray anal. identified 41 upregulated (1.22%) and 24 downregulated (0.71%) genes after tanshinone IIA treatment. Upregulated genes were involved predominantly in cycle regulation, cell proliferation, apoptosis, signal transduction and transcriptional regulation; and downregulated genes were assocd. mainly with apoptosis and extracellular matrix/adhesion mols. A 44.91% tumor mass vol. redn. and significant increase of caspase-3 protein expression were obsd. in vivo. Our findings suggest that tanshinone IIA might have potential anticancer activity on both ER-pos. and -neg. breast cancers, which could be attributed in part to its inhibition of proliferation and apoptosis induction of cancer cells through upregulation and downregulation of multiple genes involved in cell cycle regulation, cell proliferation, apoptosis, signal transduction, transcriptional regulation, angiogenesis, invasive potential and metastatic potential of cancer cells.
ADPRTL1 might be the main target at which tanshinone IIA acted.
Bibliographic Information
Active Antitumor Immunity Elicited by Vaccine Based on Recombinant Form of Epidermal Growth Factor Receptor. Hu, Bing; Wei, Yuquan; Tian, Ling; Zhao, Xia; Lu, You; Wu, Yang; Yao, Bing; Liu, Jiyan; Niu, Ting; Wen, Yanjun; He, Qiuming; Su, Jingmei; Huang, Meijuan; Lou, Yanyan; Luo, Yan; Bing, Kan. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan, Peop. Rep. China. Journal of Immunotherapy (2005), 28(3), 236-244. Publisher: Lippincott Williams & Wilkins, CODEN: JOIMF8 ISSN: 1524-9557. Journal written in English. CAN 143:113688 AN 2005:336698 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
Active immunotherapy targeting epidermal growth factor receptor (EGFR) should be another attractive approach to the treatment of EGFR-pos. tumors. To test this concept, the authors evaluated the potential immune responses and antitumor activities elicited by dendritic cells pulsed with recombinant ectodomain of mouse EGFR (DC-edMER). Spleen cells isolated from DC-edMER-vaccinated mice showed a high quantity of EGFR-specific antibody-producing cells. EGFR-reactive antibody in sera isolated from vaccinated mice was identified and shown to be effective against tumors in vitro and in vivo by adoptive transfer. DC-edMER vaccine also elicited cytotoxic T-lymphocyte responses that could mediate antitumor effects in vitro and adoptive transfer in vivo. In addn., EGFR-specific cytokines responses were elicited by DC-edMER vaccine. Immunization with DC-edMER resulted in tumor regression and prolonged survival in mice challenged with Lewis lung carcinomas and mammary cancer models. Depletion of CD4+ T lymphocytes could completely abrogate the antitumor activity and EGFR-specific antibody responses, whereas the depletion of CD8+ T lymphocytes showed partial abrogation of the antitumor activity but antibody was still detected. Furthermore, tumor-induced angiogenesis was suppressed in DC-edMER-vaccinated mice or mice treated with antibody adoptive transfer. Thus, antitumor immunity could be induced by DC-edMER, which may involve both humoral and cellular immunity, and may provide insight into the treatment of EGFR-pos. tumors through the induction of active immunity against EGFR.
Bibliographic Information
Immunotherapy of tumor by targeting angiogenesis. Hou, Jianmei; Tian, Ling; Wei, Yuquan. Key Laboratory of Biotherapy of Human Diseases of Ministry of Education, West China Hospital of Sichuan university, Chengdu, Peop. Rep. China. Science in China, Series C: Life Sciences (2004), 47(6), 545-552. Publisher: Science in China Press, CODEN: SCCLFO ISSN: 1006-9305. Journal; General Review written in English. CAN 142:334515 AN 2005:136917 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
A review. Tumor growth and metastasis are angiogenesis-dependent. Anti-angiogenic therapy represents a new strategy for the development of anti-cancer therapies. In recent years, there has been made great progress in anti-angiogenic therapy. As far as the passive immunotherapy is concerned, a recombinant humanized antibody to vascular endothelial growth factor (VEGF), Avastin, has been approved by FDA as the first angiogenesis inhibitor to treat colorectal cancer. For active specific immunotherapy, various strategies for cancer vaccines, including whole endothelial cell vaccines, dendritic cell vaccines, DNA vaccines, and peptides or protein vaccines, have been developed to break immune tolerance against important mols. assocd. with tumor angiogenesis and induce angiogenesis-specific immune responses. The authors review the angiogenesis-targeted immunotherapy of tumors from the above two aspects.
Bibliographic Information
Cancer immunotherapy of targeting angiogenesis. Hou, Jianmei; Ling, Tian; Wei, Yuquan. Key Laboratory of Biotherapy of Human Diseases of Ministry of Education and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Peop. Rep. China. Cellular & Molecular Immunology (2004), 1(3), 161-166. Publisher: Chinese Society of Immunology, CODEN: CMIEAO ISSN: 1672-7681. Journal; General Review written in English. CAN 141:378437 AN 2004:696591 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
A review. Tumor growth and metastasis are angiogenesis-dependent. Anti-angiogenic therapy may be a useful approach to cancer therapy. This review discusses tumor angiogenesis and immunotherapy of targeting tumor angiogenesis from two main aspects: (1) active vaccination to induce effective anti-angiogenesis immunity; (2) passive immunotherapy with anti-pro-angiogenic mols. relevant antibody. Evidence from the recent years suggested that anti-angiogenic therapy should be one of the most promising approaches to cancer therapy.
Bibliographic Information
Regulation of apoptotic signal transduction pathways by the heat shock proteins. Li, Zhengyu; Zhao, Xia; Wei, Yuquan. Department of Gynecology and Obstetrics, West China Second Hospital of Sichuan University, Chengdu, Peop. Rep. China. Science in China, Series C: Life Sciences (2004), 47(2), 107-114. Publisher: Science in China Press, CODEN: SCCLFO ISSN: 1006-9305. Journal; General Review written in English. CAN 140:403899 AN 2004:385792 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
A review. The study about apoptotic signal transductions has become a project to reveal the mol. mechanisms of apoptosis. Heat shock proteins (hsps), which play an important role in cell growth and apoptosis, have attracted great attentions. Research has shown there is a hsps superfamily including hsp90, hsp70, hsp60, and hsp27, etc., which regulates the biol. behaviors of cells, particularly apoptotic signal transduction in Fas pathway, JNK/SAPK pathway, and caspases pathway at different levels, partly by the function of mol. chaperone.
Bibliographic Information
Advances in identification and application of tumor antigens inducing anti-cancer responses. Xie, Ke; Tian, Ling; Deng, Hongxin; Wei, Yuquan. Key Laboratory of Biotherapy of Human Diseases of Ministry of Education of China and Cancer Center for West China Hospital, West China Medical School, Sichuan University, Chengdu, Peop. Rep. China. Chinese Science Bulletin (2003), 48(11), 1051-1054. Publisher: Science in China Press, CODEN: CSBUEF ISSN: 1001-6538. Journal; General Review written in English. CAN 140:126747 AN 2003:564343 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
A review discusses the classification of tumor antigens and the technologies of identification and application of tumor antigens. The identification of tumor antigens opened new approaches to the development of cancer vaccines and possibilities for the development of effective cancer immunotherapy protocols.
Bibliographic Information
Inhibitory effect of sulindac on the proliferation of HT-29 colon adenocarcinoma cells: effects on cell cycle and apoptosis. Yang, Zhengbing; Ouyang, Qin; Wei, Yuquan; Liu, Xiaoqin; Lei, Song. Department of Gastroenterology, First Affiliated Hospital, West China University of Medical Sciences, Chengdu, Peop. Rep. China. Chinese Journal of Digestive Diseases (2001), 2(1), 30-33. Publisher: Blackwell Publishing Asia Pty Ltd., CODEN: CJDDA9 ISSN: 1443-9611. Journal written in English. CAN 139:190796 AN 2003:94558 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
Objective was to investigate: (i) the effect of sulindac on the proliferation of HT-29 cells; and (ii) the antineoplastic mechanisms of sulindac. The MTT colorimetric assay was used to examine the effect of sulindac on the proliferation of HT-29 cells. Flow cytometry was used for examg. the cell cycle distribution. Flow cytometry, TEM and DNA electrophoresis were used to det. whether sulindac induces cell apoptosis. Sulindac inhibited cell proliferation in a time- and dose-dependent manner. After treatment with 0.3, 0.6, 0.9 and 1.2 mmol/L sulindac for 72 h, the inhibition rates reached 16, 38, 62.3 and 92.2%, resp. After treatment with 1.2 mmol/L sulindac for 24, 48 and 72 h, the inhibition rates reached 32.4, 71.3 and 92.2%, resp. (P < 0.05). Sulindac increased the proportion of cells in the G0/G1 phase and decreased the proportion of cells in the S phase of the cell cycle. After treatment with 1.2 mmol/L sulindac for 48 h, the proportion of cells in the G0/G1 phase increased from 32.5 to 70.5% and the S phase decreased from 43.1 to 11.3% compared with the control cells (P < 0.01). Flow cytometry, DNA electrophoresis and TEM all demonstrated that sulindac could induce apoptosis of the HT-29 cell line. After treatment with 0.3, 0.6 and 1.2 mmol/L sulindac for 48 h, the proportion of apoptotic cells reached 5.8, 7.6 and 11.7%, compared with 2.9% in the control group; after treatment for 72 h, the proportion of apoptotic cells increased to 12.5, 15.4% and 24.2%, resp. (P < 0.05). All effects were time and dose dependent. The colon adenocarcinoma HT-29 cell line can be inhibited by sulindac and the antitumor mechanism may be related to changing cell cycle distribution and inducing cell apoptosis.
Bibliographic Information
Xenogeneic homologous genes, molecular evolution and cancer therapy. Tian, Ling; Wei, Yuquan. Center for Biotherapy of Cancer and Cancer Research Center, First University Hospital, West China Medical Center, Sichuan University, Chengdu, Peop. Rep. China. Progress in Natural Science (2001), 11(12), 893-904. Publisher: Science in China Press, CODEN: PNASEA ISSN: 1002-0071. Journal; General Review written in English. CAN 137:4552 AN 2002:17265 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
A review which discusses cancer biotherapy with xenogeneic homologous genes. Cancer is one of the main causes for death of human beings to date, and cancer biotherapy (mainly immunotherapy and gene therapy) has become the most promising approach after surgical therapy, radiotherapy and chemotherapy. However, there are still many limitations on cancer immunotherapy and gene therapy; therefore great effort is being made to develop new strategies. It has been known that, in the process of evolution, a no. of genes, the so-called xenogeneic homologous genes, are well-conserved and show the structural and/or functional similarity between various species to some degree. The nucleotide changes between various xenogeneic homologous genes are derived from mutation, and most of them are neutral mutations. Considering that the subtle differences in xenogeneic homologous genes can break immune tolerance, enhance the immunogenicity and induce autologous immune response to eliminate tumor cells, the authors expect that a strategy of inducing autoimmune response using the property of xenogeneic homologous genes will become a new therapy for cancer. Moreover, this therapy can also be used in the treatment of other diseases, such as autoimmune diseases and AIDS. This article will discuss the xenogeneic homologous genes, mol. evolution and cancer therapy.
Bibliographic Information
Change of apoptotic status in the human colorectal adenoma-carcinoma sequences and its correlation with carcinogenesis and prognosis. Li, Li; Yan, Lunan; Wang, Zhong; Liu, Zhanpei; Wei, Yuquan; Huang, Guangqi. Department of General Surgery, First Affiliated Hospital, West China University of Medical Sciences, Chengdu, Peop. Rep. China. Chinese Medical Journal (Beijing, English Edition) (2000), 113(10), 886-888. Publisher: Chinese Medical Association, CODEN: CMJODS ISSN: 0366-6999. Journal written in English. CAN 134:220578 AN 2000:775262 CAPLUS (Copyright (C) 2006 ACS on SciFinder (R))
Abstract
The objective was to assess apoptotic status during the development of colorectal cancer and its prognostic value. The apoptotic frequency of 168 fresh adenocarcinoma specimens and primary cultured cells at 2, 12, 24 and 48 h (9 normal mucosa, 4 adenomas and 9 adenocarcinomas) were measured by flow cytometry (FCM). Apoptotic indexes (AI) in situ for 25 adenomas and 77 adenocarcinomas were visualized by TdT-mediated dUTP nick end labeling (TUNEL), Ki-s5 labeling indexes, (KI), bcl-2, bax, waf1 and p53 were immunostained with ABC method. The culture-related apoptosis at 24-48 h in vitro was obviously decreased in cultured tumor cells when compared with mucosa cells. Spontaneous apoptosis in situ occurred more frequently in tumor with aneuploid type at late stage. There was pos. relationship between apoptosis and proliferative activity, detd. by both TUNEL and FCM methods. The well-differentiated or early stage lesions with intensive bcl-2/bax expression were significantly more likely to have low AI. P53 accumulation and waf1 depression were mainly related to KI, whereas bax and waf1 overexpression led to a comparatively higher AI/KI ratio. Bcl-2 and KI were found to be independent risk factors. The data suggest that the depressed susceptibility to inductive apoptosis may contribute to the initial phase of tumorigenesis, and spontaneous apoptosis in vivo may serve as a marker of tumor progression. The bcl-2 and KI may be valuable in predicting prognosis in colorectal cancer.